Clinical outcome of Henipavirus infection in hamsters is determined by the route and dose of infection by Rockx, B. (Barry) et al.
JOURNAL OF VIROLOGY, Aug. 2011, p. 7658–7671 Vol. 85, No. 15
0022-538X/11/$12.00 doi:10.1128/JVI.00473-11
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Clinical Outcome of Henipavirus Infection in Hamsters Is Determined
by the Route and Dose of Infection
Barry Rockx,1,3* Douglas Brining,2 Joshua Kramer,4 Julie Callison,1 Hideki Ebihara,1
Keith Mansfield,4 and Heinz Feldmann1
Laboratory of Virology,1 Rocky Mountain Veterinary Branch,2 Division of Intramural Research, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Hamilton, Montana; Departments of Pathology and Microbiology & Immunology,
University of Texas Medical Branch, Galveston, Texas3; and Harvard Medical School, Southborough, Massachusetts4
Received 8 March 2011/Accepted 10 May 2011
Nipah virus (NiV) and Hendra virus (HeV) are emerging zoonotic viruses and the causative agents of severe
respiratory disease and encephalitis in humans. Little is known about the mechanisms that govern the
development of respiratory and neurological disease. Using a hamster model of lethal NiV and HeV infection,
we describe the role of the route and dose of infection on the clinical outcome and determine virus tropism and
host responses following infection. Infection of hamster with a high dose of NiV or HeV resulted in acute
respiratory distress. NiV initially replicated in the upper respiratory tract epithelium, whereas HeV initiated
infection primarily in the interstitium. In contrast, infection with a low dose of NiV or HeV resulted in the
development of neurological signs and more systemic spread of the virus through involvement of the endo-
thelium. The development of neurological signs coincided with disruption of the blood-brain barrier (BBB) and
expression of tumor necrosis alpha (TNF-) and interleukin 1  (IL-1). In addition, interferon-inducible
protein 10 (IP-10) was identified as playing an important role in NiV and HeV pathogenesis. These studies
reveal novel information on the development and progression of NiV and HeV clinical disease, provide a
mechanism for the differences in transmission observed between NiV and HeV outbreaks, and identify specific
cytokines and chemokines that serve as important targets for treatment.
Hendra virus (HeV) and Nipah virus (NiV) are two mem-
bers of the genus Henipavirus (family Paramyxoviridae) that
cause severe respiratory illness and encephalitis in humans.
HeV was the first member of the genus to be identified as the
causative agent of an acute respiratory disease in horses in
1994 (30), and to date there have been 14 outbreaks in Aus-
tralia, with at least one occurrence per year since 2006, most
recently in May 2010. Only 7 human infections with HeV have
been identified, of which 4 were fatal (57%) (25, 30, 36)
(ProMed-Mail no. 20090903.3098). All patients initially pre-
sented with influenza-like illnesses (ILI) after an incubation
period of 7 to 16 days. Lethal cases either developed pneumo-
nitis and died from multiorgan failure or developed encepha-
litic manifestations (mild confusion and ataxia) and seizures.
The first cases of NiV were identified during an outbreak of
severe febrile encephalitis in Malaysia and Singapore in 1998-
1999 (9). A total of 276 patients with encephalitis were re-
ported with 106 fatalities (38%). The primary mode of trans-
mission to humans was believed to be pig to human, as this
outbreak involved widespread respiratory disease in pigs and
occupational exposure to pigs (1, 8). Since this outbreak, re-
current outbreaks of NiV in Bangladesh and India have in-
volved more than 120 people (7, 16, 18). These outbreaks were
associated with significantly higher case fatality rates, ranging
from 67% to 92%. In addition, a higher prevalence of respi-
ratory disease was observed during these outbreaks (18), and
person-to-person contact with a patient carried a high risk of
transmission (14, 15, 19).
Histopathological changes in the central nervous system
(CNS) of fatal human HeV and NiV cases included systemic
vasculitis and parenchymal necrosis, while in the lung, patho-
logical findings included mainly vasculitis, fibrinoid necrosis,
alveolar hemorrhage, pulmonary edema, and aspiration pneu-
monia (23, 36). Other organs that were affected included heart,
kidney, and spleen and showed generally mild or focal inflam-
mation. The development of syncytial multinucleated endothe-
lial cells is characteristic for both HeV and NiV (36, 37). At
present, the details on the pathogenesis and histopathological
changes mediated by either HeV or NiV infection in humans is
naturally derived from only the terminal stage of the disease.
Therefore, in order to study pathogenesis over the time course
of infection, a relevant animal disease model is needed that
mimics the disease progression seen in humans.
Henipaviruses display a broad species tropism, and NiV has
naturally infected several species of bats as well as pigs, hu-
mans, dogs, horses, and cats (34). Nonhuman primate models
for both HeV and NiV and a ferret model for NiV have been
described that mimic the clinical outcome observed with hu-
mans (4, 11, 29). Currently the only small-rodent disease
model that mimics both HeV and NiV infection in humans is
the Syrian golden hamster (13, 35). In this model both HeV
and NiV infection via the intraperitoneal (i.p.) route caused
primarily neurological disease; however, respiratory distress
and sanguinous froth exuding from nares was observed in some
HeV-infected animals. Interestingly, the majority of animals
infected with NiV via the intranasal (i.n.) route developed
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neurological symptoms as well as labored breathing in the
final stages of disease (35), while no information is available
on i.n. infection of hamsters with HeV. The main histo-
pathological findings included parenchymal infection in var-
ious organs, including the brain and lung, with vasculitis and
multinucleated syncytial cells in the endothelium of many
blood vessels (13, 35).
Limited information is available about the pathogenesis of
HeV and NiV infection, and it is unknown what factors are
involved in the development of either acute respiratory or
neurological disease. We previously hypothesized that while a
high dose of HeV resulted in the development of acute respi-
ratory distress in the African green monkey model, a low dose
would result in primarily neurological signs (29). Here we
compare the pathogenesis of high- and low-dose infections of
HeV and NiV in a lethal hamster model to more fully under-
stand the impact of infection route and dose on the clinical
outcome of disease. In addition, we characterize the host re-
sponse following HeV and NiV infection.
MATERIALS AND METHODS
Ethics statement. Approval for animal experiments was obtained from the
Rocky Mountain Laboratories (RML) Institutional Animal Care and Use Com-
mittee, Division of Intramural Research (DIR), National Institute of Allergy and
Infectious Diseases (NIAID), National Institutes of Health (NIH). Animal work
was performed by certified staff in an Association for Assessment and Accredi-
tation of Laboratory Animal Care (AAALAC)-approved facility. Animal hous-
ing, care, and experimental protocols were in accordance with NIH guidelines.
Viruses and cells. HeV (GenBank no. AF017149) and NiV (Malaysia strain;
GenBank no. AF212302) were kindly provided by the Special Pathogens Branch
of the Centers for Disease Control and Prevention, Atlanta, GA. The viruses
were propagated on Vero E6 cells in Dulbecco’s minimal essential medium
(DMEM) supplemented with 10% fetal calf serum (HyClone; Logan, UT),
L-glutamine, penicillin, and streptomycin at 37°C in a humidified CO2 incubator
(5%). All infectious work was performed in a class II biological safety cabinet in
a biosafety level 4 (BSL4) laboratory at the RML, DIR, NIAID, NIH.
Animal infection. Female Syrian golden hamsters (Mesocricetus auratus;
6-week-old HsdHan:AURA hamsters from Harlan Laboratories) were anesthe-
tized by chamber induction (5 liters 100% O2/min and 3 to 5% isoflurane). Each
hamster was inoculated either intranasally (i.n.) with a 100-l volume or intra-
peritoneally (i.p.) with a 200-l volume of HeV, NiV, or phosphate-buffered
saline (PBS). To determine the lethal dose at which 50% of the animals suc-
cumbed to infection (LD50), groups of 5 animals were infected with 1, 10, 102,
103, 104, or 105 tissue culture doses leading to a 50% cytopathic effect (50%
tissue culture infective dose [TCID50]) of either HeV or NiV by i.n. or i.p.
inoculation. The LD50 was calculated by the Reed-Muench method. To compare
the pathogenesis levels of HeV and NiV infection, groups of 5 animals were
infected with either 102 or 105 TCID50 of HeV or NiV by i.n. inoculation.
Animals were monitored daily for weight loss and clinical signs. For the patho-
genesis study, groups of 5 animals were euthanized on various days postinfection
(p.i.), and whole-blood samples (EDTA Vacutainer) as well as liver, spleen,
kidney, bladder, trachea, left and right lung, heart, and brain (frontal, cerebel-
lum, and stem) were removed for virus isolation, RNA extraction, and histolog-
ical examination. Following necropsy, lungs were weighed as well as scored for
the percentage of lesions.
To determine the permeability of the blood-brain barrier (BBB) during the
induction of neurological disease by HeV and NiV infection, groups of 5 animals
were challenged with 102 TCID50 of HeV or NiV by i.n. inoculation. On days 5
(HeV) or 10 (NiV) p.i., animals were injected with 1 ml of a sterile 1% Evans
blue (Sigma-Aldrich) solution in PBS by the i.p. route. Twenty-four hours after
injection, animals were euthanized and transcardially perfused (60 ml PBS to
remove access Evans blue in the blood), and brains removed.
Chest radiographs. A mobile digital radiography unit with a flat-panel digital
detector (Sound Technologies Tru/Dr) and a portable X-ray generator (Poskom
model PXP-HF) was used to acquire chest radiographs. The unit operates on
veterinary-specific software system (VetPACS). Radiographic views acquired
included ventrodorsal, right lateral, and left lateral thoracic images captured
while the animals were under anesthesia.
Virus titrations. Tissue samples were weighed and homogenized in 10 equiv-
alent volumes of DMEM to generate a 10% solution. The solution was centri-
fuged at 10,000 rpm under aerosol containment in a tabletop centrifuge for 5 min
to pellet insoluble parts. Virus titration was performed using a TCID50 assay on
96-well plates (1 104 Vero E6 cells per well) with 100 l inoculum from 10-fold
serial dilutions. Plates were incubated for 3 days at 37°C, and wells were scored
for cytopathic effect (CPE). Virus concentrations were calculated as the TCID50
per gram tissue.
RNA isolation and quantitative real-time PCR (RT-PCR) assays. Approxi-
mately 100 mg of tissue was stored in 1 ml RNAlater (Qiagen, Inc.) for 7 days at
4°C to stabilize RNA. RNAlater was completely removed, and tissues were
homogenized and inactivated in 1 ml Trizol (Life Technologies) in a 2-ml cry-
ovial using the Qiagen TissueLyser and stainless steel beads prior to removal
from the BSL4 laboratory. Subsequently, RNA was isolated from tissues accord-
ing to the manufacturer’s instructions.
Host gene expression was determined as previously described (38). Briefly, the
primers and probe that target the hamster interferon-inducible protein 10 (IP-
10), gamma interferon (IFN-), tumor necrosis factor alpha (TNF-), ribosomal
protein L18 (RPL18), interleukin-1 (IL-1), IL-4, IL-6, and IL-10 were used,
and a one-step RT-PCR was done using Rotor-Gene Multiplex RT-PCR kits
(Qiagen, Inc.). All RT-PCR mixtures contained 2 l of RNA. Master mixes were
set up according to the manufacturer’s protocols. Each reaction was done in a
total volume of 25 l. Test samples were assayed using the Rotor Gene 6000
detection system (Qiagen, Inc.) with the following parameters: 50°C for 10 min,
95°C for 5 min, and 40 cycles of 95°C for 5 s, 60°C for 10 s. Threshold cycle (CT)
values representing hamster gene expression were analyzed with Rotor Gene
6000 software. The change for each gene was calculated using the mean of the
change in CT values (CT) normalized to the CT values of RPL18 for each
sample (2CT).
Histopathology and immunohistochemistry. All tissue samples were immer-
sion fixed in 10% neutral buffered formalin for at least 7 days under BSL4
conditions. Prior to removal from the BSL4 laboratory, formalin was changed
and specimens were processed under BSL2 conditions by conventional methods,
embedded in paraffin, sectioned at a 5-m thickness, and stained with hematox-
ylin and eosin (H&E). Tissues for immunohistochemistry were stained on the
Discovery XT automated stainer (Ventana Medical Systems) using an anti-
Nipah nucleoprotein antibody (1:5,000; kindly provided by C. Broder, Uni-
formed Services University, Bethesda, MD) and the DAB map detection kit
(Ventana Medical Systems) (21). Nonimmune rabbit IgG was used as a negative
staining control.
H&E-stained sections of lung, liver, spleen, kidney, bladder, brain, trachea,
and skull (including nasal mucosa, olfactory cortex, cranial nerves, eyes, muscle,
teeth, and bone in step sections) were examined for all animals by a pathologist.
Pulmonary lesions were assigned a subjective score from to based on the
severity of the lesions. In general, a score of  was given to those lungs with
small, multifocal areas of peribronchial or random inflammation affecting 	10%
of the examined tissue. A score of  was given to those lungs with more severe
inflammation, involving a larger percentage of lungs, 10 to 50%, but not yet
entire lobes. A score of  was given to those lungs in which inflammation,
edema, hemorrhage, and/or necrosis affected entire lung lobes or the majority of
multiple lobes. A similar scoring system was used to assess the nasal mucosa and
tracheal epithelium. For these tissues, scores of , , and  represented
mild, moderate, and severe histopathological changes, respectively. No scores
were assessed for any other organs, and only the presence or absence of lesions
was noted.
Immunohistochemistry using an anti-Nipah virus antibody was performed on
lung, trachea, skull, and brain for a subset of cases, and these slides were
examined by a pathologist. Lesions were assigned a score of  to  as
described above for hematoxylin-and-eosin-stained sections.
RESULTS
Route and dose of infection determines clinical outcome.
Syrian golden hamsters (Mesocricetus auratus) have previously
been shown to be susceptible to infection with NiV and HeV
(13, 35). In order to directly compare the virulence of HeV and
NiV infection in this model, animals were inoculated with
10-fold dilutions (1 to 105 TCID50) of HeV or NiV by the i.n.
or i.p. route. The LD50 of animals by the i.n. and i.p. route was
	1 and 6 TCID50, respectively, and were identical for both
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NiV and HeV (data not shown). The average time to death of
animals infected with 102 TCID50 of virus via the i.n. route was
significantly longer in NiV-infected animals (12 days) com-
pared to HeV (7.5 days) (t test; P 	 0.05). No significant
differences in time to death were observed between NiV and
HeV at a dose of 105 TCID50 or following i.p. challenge.
General signs included significant weight loss (
20%), re-
duced activity, and reluctance to move. Interestingly, animals
infected with a high dose of NiV or HeV succumbed due to an
acute onset of severe respiratory distress, whereas animals
infected with a lower dose developed respiratory disease that
progressed to neurological signs. Neurological signs included
partial or complete paralysis, muscle fasciculations, and sei-
zures. Respiratory signs included labored breathing and sero-
sanguineous nasal and oral exudates.
Based on the differential clinical outcome due to the route
and dose of infection, animals were challenged in subsequent
experiments with either a high or low dose to induce a primar-
ily respiratory or neurological disease, respectively.
Effect of NiV and HeV challenge doses. i.n. challenge of
hamsters with a high dose (105 TCID50) of HeV resulted in
weight loss as early as day 2 p.i. (Fig. 1A). By day 3 p.i., all
remaining HeV-infected animals were euthanized due to se-
vere acute respiratory distress. Interestingly, animals infected
with NiV showed a delay in weight loss and the development of
respiratory signs by 2 days (Fig. 1A). Upon necropsy, the de-
FIG. 1. The effect of infectious dose on the clinical outcome of HeV and NiV virus infection. Weight loss (A and B), percent lung lesions (C
and D), and percent lung weight per body weight (E and F) results are shown for 6-week-old hamsters infected with a high (A, C, and E) or low
(B, D, and F) dose of HeV (gray) and NiV (black). For panels A and B, body weights of infected hamsters were measured on a daily basis (n 
5 per group). Weight changes are expressed as the mean percent changes for infected animals relative to their weights at day zero. For panels C
and D, gross pathological lung lesions are expressed as the mean percentage of the lung surface covered by lesions (n  5 per group). For panels
E and F, wet lung weights were measured for 5 animals per group each day and expressed as the percentage of lung weight per body weight. Error
bars represent standard deviations.
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velopment of macroscopic lung lesions in infected animals
coincided with, and was reciprocal to, weight loss (Fig. 1C). Up
to 100% of the lungs were affected by day 3 and 5 p.i. with HeV
and NiV, respectively. Lung wet weights were taken as an
indicator of inflammation and edema. A 
2-fold increase in
lung weight could be observed with both HeV- and NiV-in-
fected animals (Fig. 1E). Coinciding with weight loss and lung
lesions, HeV infection resulted in a faster increase in lung
weight compared to NiV infection.
A low-dose (102 TCID50) i.n. challenge of NiV or HeV
resulted in a more variable outcome of disease compared to
the high-dose challenges. HeV challenge resulted in weight
loss on days 6 and 7 p.i. (Fig. 1B). By day 7 all HeV-infected
animals had to be euthanized due to the development of severe
acute respiratory distress as well as the development of neu-
rological signs as described above. Animals infected with NiV
did not lose weight but did develop neurological signs as early
as 9 days p.i. (Fig. 1B). By day 12 all remaining animals were
euthanized due to the development of severe neurological
signs. No overt respiratory signs were noticed in these animals.
Lung lesions were detected in HeV-infected animals by day
5 p.i. and covered as much as 100% of the lungs in some
animals (Fig. 1D). Lung lesions were also observed in NiV-
infected animals on day 9 (Fig. 1D). Interestingly, in NiV-
infected animals, lung lesions were clearing on day 10 with only
minimal lesions in a few infected animals by days 11 and 12. In
accordance with the development of lung lesions, the lung
weight of HeV-infected hamsters started to increase by day
5 p.i. and was increased 2-fold by day 6 (Fig. 1F). In NiV-
infected animals, the lung weight was increased only on day
9 p.i., in agreement with the transient development of lung
lesions in these animals (Fig. 1F).
Radiological changes in NiV- and HeV-infected hamsters.
Respiratory disease development was also analyzed by radio-
graphic imaging (X ray). Thoracic radiographic evaluation of
both high-dose NiV- and HeV-infected animals was character-
ized by radiographic changes as early as day 2 p.i. (Fig. 2A and
B). Moderate interstitial infiltrates and areas of consolidation
were evident in both groups by day 2. Both groups were char-
acterized by rapidly progressive increases of pulmonary infil-
trates throughout the lung fields and the formation of air
bronchograms. These changes were seen to peak at day 3 p.i.
for the HeV-infected animals and at day 5 p.i. for the NiV-
infected animals (Fig. 2A and B). Thoracic radiographic
changes in animals infected i.n. with a low dose of NiV in-
cluded diffuse pulmonary interstitial infiltrates first noted on
day 5 p.i. (Fig. 2C). Peak radiographic changes were noted on
day 9 p.i., with air bronchograms and diffuse pulmonary inter-
stitial infiltrates resulting in complete effacement of the cardiac
silhouette. There was a gradual resolution of pulmonary infil-
trates on days, 10, 11, and 12. The earliest detectable radio-
graphic changes in animals infected with a low dose of HeV
showed focal areas of patchy consolidation in the caudal lung
lobes by day 3 p.i. (Fig. 2D). Radiographic lesions were pro-
gressively more significant on days 5, 6, and 7. Peak lesions
were noted on day 7 p.i. and showed complete effacement of
the cardiac silhouette by diffuse pulmonary interstitial infil-
trates and detectable air bronchograms.
Virus replication and tissue tropism. A high-dose NiV chal-
lenge resulted in efficient virus replication primarily in the
respiratory tract (Fig. 3A) with peak titers of 106 TCID50/gram
of tissue in trachea and lungs in all animals. Virus replication
in the spleen was observed in 1 animal on day 2 p.i., whereas 1
animal had infectious virus in the brain on day 5 p.i. HeV
replication in animals infected with a high dose was found
primarily in the respiratory tract (Fig. 3B) with peak titers of
106 TCID50/gram of lung tissue. In the trachea, infectious virus
was found only on days 2 and 3 p.i. In contrast to respiratory
tract tropism of NiV infection, low levels of HeV replication
were detected in a variety of organs, including spleen, kidney,
heart, and brain tissue, suggesting a more systemic spread of
the virus (Fig. 3B). Interestingly, no infectious virus could be
detected in the blood of either NiV- or HeV-infected animals
(data not shown).
Virus replication in the lungs of hamsters infected with a low
dose of NiV was 2 logs lower than those infected with a high
dose (Fig. 3C). Infectious virus could be detected in the lungs
from days 3 to 7 p.i. Interestingly, NiV could be detected in
brain tissue as early as day 7 p.i., with peak titers of 106
TCID50/gram of brain tissue on day 9 p.i. In addition to the
lungs and brain, NiV could also be detected in the kidney. A
low-dose HeV challenge resulted in systemic spread of the
virus to the majority of tissues tested (Fig. 3D). HeV was
isolated from the lung early during infection on days 1 and
3 p.i. but by day 5 was spread to all other tissues, including the
brain. The highest titers of HeV were found in the brain on day
7 p.i., peaking at 107 TCID50/gram of brain tissue. Again, no
infectious virus was detected in the blood of either NiV- or
HeV-infected animals (data not shown).
Cell tropism of NiV and HeV. Infection with both HeV and
NiV at a high dose caused primarily pulmonary and upper
respiratory lesions (Fig. 4 and Table 1). Lesions were similar
between groups but more severe and occurred at earlier time
points in HeV-infected animals than in NiV-infected animals
(Table 1). Animals in both groups developed necrosuppurative
rhinitis (Fig. 4) characterized by variably degenerate nasal ep-
ithelium and a mixed submucosal inflammatory infiltrate
composed of mononuclear cells admixed with numerous neu-
trophils. In both groups, infection began as bronchial or peri-
bronchial inflammation, rapidly spreading to the interstitium
and ultimately involving pulmonary vessels (data not shown
and Fig. 4). Lesions at days 1 and 2 p.i. were characterized by
peribronchial neutrophilic and histiocytic infiltrates, small mul-
tifocal areas of consolidation, and the rare involvement of
small blood vessels, which was especially prominent in HeV-
infected animals (data not shown). Viral syncytial cells were
often seen in bronchial epithelium and multifocally in areas of
inflammation, and these sometimes contained intracytoplasmic
eosinophilic viral inclusions (data not shown).
During the late stage of disease (days 3 and 5 for HeV and
NiV, respectively), there were widespread areas of necrohem-
orrhagic bronchopneumonia in both NiV- and HeV-infected
animals (Fig. 4), with HeV-infected animals also showing se-
vere perivascular hemorrhage. The bronchial epithelium was
variably necrotic in both groups and rarely included epithelial
syncytial cells (Fig. 4). There was peribronchial, interstitial,
and perivascular hemorrhages, especially severe in HeV-in-
fected animals (Fig. 4). Alveolar lumina were obstructed by a
predominantly mononuclear inflammatory cell infiltrate with
occasional large viral syncytial cells containing small eosiniphi-
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lic intracytoplasmic inclusion bodies (Fig. 4). Again, hemor-
rhage was a striking feature in HeV-infected animals (Fig. 4).
Vascular involvement with endothelial syncytial cell formation
and transmural necrotizing vasculitis became more prominent
at day 2 p.i. in HeV-infected animals and at days 3 and 4 p.i. in
NiV-infected animals (date not shown). This was a major fea-
ture by day 3 p.i. in HeV-infected animals and day 5 p.i. in
NiV-infected animals (Fig. 4). Alveolar hemorrhage, edema,
and fibrin exudation increased as the severity of vascular le-
sions increased and were more severe in HeV-infected animals
than in NiV-infected animals.
Viral nucleocapsid protein (NP) expression in lungs of ham-
sters infected with a high dose of NiV or HeV generally coin-
cided with an increasing severity of histopathological changes
(Fig. 5 and Table 1). The nasal mucosa stained positive in both
groups (data not shown), and interestingly, viral NP was de-
tected only in the tracheal epithelium of NiV-infected animals
early during infection (Fig. 5 and Table 1). In the NiV-infected
animals, viral antigen was noted in the trachea, bronchi, and
interstitium from days 1 to 3 p.i. and spread to the vessels at
days 4 and 5 p.i., as tracheal staining was absent and bronchial
staining intensity waned (Table 1). In HeV-infected animals,
no viral antigen was detected in the tracheal epithelium at any
time point (Fig. 5 and Table 1). Viral antigen was most abun-
FIG. 2. Radiological examination of the lungs of NiV- and HeV-infected hamsters. Hamsters were infected with a high (A and B) or low (C
and D) dose of NiV (A and C) or HeV (B and D). Radiographic images (X-ray) were taken from each group (n  5) prior to euthanasia. Shown
are X-rays of a representative animal from each group. White arrows represent earliest detectable radiographic changes. Black arrows represent
discernible air bronchograms.
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dant in multifocal peribronchial areas in the interstitium early
during infection which became more prevalent by days 2 and
3 p.i. (Fig. 5). HeV spread to the vessels at day 2 p.i. and,
unlike NiV, was uncommon in the bronchial epithelium at all
time points (Fig. 5 and Table 1). Pulmonary vessels showed the
presence of viral antigen in both endothelial cells and trans-
murally through vascular smooth muscle. No viral antigen was
observed in the brains of any animals (Table 1).
FIG. 3. Virus replication in NiV- and HeV-infected hamsters. Organs were harvested from hamsters infected with a high (A and B) or low (C
and D) dose of NiV (A and C) or HeV (B and D) on various days postinfection as described in Materials and Methods. Tissue samples from 5
animals per group were analyzed at each time point. Error bars represent standard deviations.
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In contrast to the high-dose infections, low-dose infections
with both HeV and NiV caused lesions in all organs examined,
including heart, liver, kidneys, bladder, brain, lungs, and nasal
epithelium (data not shown). Pulmonary lesions in the low-
dose groups were similar to those in the high-dose groups but
had a more protracted course (Table 1). As with the high-dose
infections, HeV-infected animals had a more rapid onset of
pathological changes, and these changes tended to be more
severe compared to those for NiV.
Involvement of nonrespiratory organs began by day 5 p.i. in
HeV-infected animals and on day 9 p.i. in NiV-infected ani-
mals and continued through the completion of the study (data
not shown). Consistent with vascular spread, changes were
generally noted in multiple organs of the same animal and
were characterized by multifocal neutrophilic, histiocytic, and
lymphocytic inflammation with or without necrotizing vasculi-
tis (data not shown). Brain lesions were characterized by mod-
erate or severe lymphohistiocytic meningitis with or without
vasculitis (Fig. 6), with multifocal areas of neuropil vacuola-
tion, hemorrhage, neuronal necrosis, and gliosis. Lesions were
FIG. 4. Histopathological comparison of high-dose NiV- and HeV-infected animals to control animals (PBS). Lung sections were stained with
H&E as described in Materials and Methods, and light photographs of the nasal epithelium, lung, bronchi, interstitium, alveoli, and pulmonary
vessels of 6-week-old hamsters inoculated with PBS, NiV, or HeV are shown. Nasal epithelium: day 2 p.i.; magnification, 40. Lung: days 5 and
3 p.i. for NiV and HeV, respectively; magnification, 2. Bronchi and interstitium: days 5 and 3 p.i. for NiV and HeV, respectively; magnification,
20. Arrow, epithelial syncytial cells; asterisk, perivascular hemorrhage. Aveoli: days 5 and 3 p.i. for NiV and HeV, respectively; magnification,
40. Arrow, syncytial cells; arrowhead, eosinophilic intracytoplasmic inclusion bodies; asterisk, hemorrhage. Pulmonary vessels: days 5 and 3 p.i.
for NiV and HeV, respectively; magnification, 20. Arrow, endothelial syncytial formation; arrowhead, transmural necrotizing vasculitis.
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randomly distributed throughout the brain, affecting the cere-
brum, cerebellum, hippocampus, and olfactory cortex simulta-
neously.
Immunohistochemical staining for NiV and HeV NP in tis-
sues of hamsters infected with a low dose showed strong anti-
gen positivity in the lungs and brain of both HeV- and NiV-
infected animals (Table 1). In the lungs, immunohistochemical
(IHC) staining was most intense in the interstitium and pul-
monary vessels, with rare staining in bronchi (Table 1). Brains
stained positive for viral antigen beginning at day 5 p.i. in
HeV-infected animals and day 9 p.i. in NiV-infected animals
(Fig. 6 and Table 1). Blood vessels (Fig. 7A), neurons (Fig.
7B), glial cells (Fig. 7C), neuropil (Fig. 6), ependyma, and
meninges (Fig. 6) all stained positive for viral antigen, consis-
tent with vascular spread. In the HeV-infected animals, the
endothelium of small cerebral blood vessels stained positive
before other cells in the brain (Fig. 7A), lending further sup-
port for the vascular spread of the virus. No staining in the
cranial nerves of any animal was observed, though small blood
vessels adjacent to facial nerve bundles were rarely immuno-
reactive (data not shown).
BBB permeability. The effect of NiV and HeV infection on
the permeability of the BBB was determined with hamsters
inoculated with NiV and HeV by staining with Evans blue.
With an intact BBB, Evans blue will not penetrate the brain;
however, as the BBB breaks down, Evans blue is allowed into
the central nervous system (CNS). A breakdown of the blood-
brain barrier occurred only in animals that displayed neuro-
logical signs, as demonstrated by the presence of Evans blue in
the brains of these animals (Fig. 8). No sign of positive staining
of the brain was shown in any of the control hamsters inocu-
lated with PBS. In contrast, deep-blue-stained lesions were
visible on both the dorsal and ventral surfaces of the brains of
NiV-infected animals showing severe neurological signs, in-
cluding partial or complete paralysis of the hind legs. In HeV-
infected animals there was light-blue staining of both the dor-
sal and ventral surfaces of the brain in animals with mild
neurological signs.
Host gene expression in lungs and brain of NiV- and HeV-
infected hamsters. In order to elucidate the molecular mech-
anisms of HeV and NiV pathogenesis, the host gene expres-
sion of several cytokines and chemokines was determined in
lung and brain tissues of infected versus uninfected hamsters.
A high dose of either NiV or HeV challenge resulted in the
upregulation of IP-10 and several cytokines, including IL-6,
IL-4, and IFN- in the lung (Fig. 9A, B, C, and D). While IP-10
upregulation was detected as early as day 1 p.i. in HeV-in-
fected lungs, peak expression levels for this chemokine, IL-6,
IL-4, and IFN- were observed later in the disease on days 2
and 3 and day 5 p.i. for HeV- and NiV-infected animals,
respectively. Induction of IP-10 resulted in an up-to-178-fold
increase. TNF- expression was upregulated only early during
NiV and HeV infection in the lungs (Fig. 9G).
Interestingly a low-dose infection of NiV and HeV resulted
in early downregulation of many of the chemokines and cyto-
kines in the brain (Fig. 9). In agreement with observations of
upregulation in the lungs of animals infected with NiV and
HeV, IP-10 was also highly upregulated in the brain with peak
changes 240-fold for HeV and 37-fold for NiV-infected ani-
mals (Fig. 9A). However, upregulation of gene expression was
delayed compared to that in the lungs of animals infected with
a high dose. In fact, downregulation was observed during the
early stages of HeV and NiV infection (first 3 or 5 days,
respectively). Expression of IL-6, IL-4, IFN-, IL-10, and
IL-1 was downregulated in the brain during the early stages of
NiV infection, with upregulation apparent only by day 10 p.i.
TABLE 1. Severity of histopathological changes in lung and virus tropism in lung and brain of Hendra virus- and
Nipah virus-infected hamstersa
Dose Virus Daypostinfection Lung score
Immunohistochemistry
Tracheal
epithelium Bronchi
Pulmonary
vessels Interstitium Brain
High (105 TCID50) Hendra 1      
2      
3   /   
Nipah 1  /    
2      
3    /  
4  /  /  
5      
Low (102 TCID50) Hendra 1     / 
3      
5   /   /
6      
7      
Nipah 5      
7    /  
9      /
10      
11      
12      
a Lung score and immunohistochemistry: , absence of lesions; , inflammation affecting 	10% of tissue; , inflammation affecting 10 to 50% of tissue; ,
inflammation affecting 
50% of tissue; /, inflammation in some but not all animals.
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FIG. 5. Tropism of lethal Nipah virus (NiV) and Hendra virus (HeV) in trachea, bronchi, interstitium, and pulmonary vessels of hamster
infected with a high dose at various days postinfection. Lung sections were stained for NiV and HeV nucleoprotein as described in Materials and
Methods. Trachea: NiV days 2 and 5 p.i., HeV days 2 and 3 p.i.; magnification,40. Bronchi and interstitium: NiV days 2 and 5 p.i. (magnification,
20 and 40, respectively), HeV days 1 and 3 p.i. (magnification, 20 and 40, respectively). Arrow, syncytial cells; arrowhead, cells in
interstitium. Pulmonary vessels: day 5 and 3 for NiV and HeV, respectively; magnification, 40. Arrow, vascular endothelial cells and smooth
muscle.
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(Fig. 9B to F). These cytokine genes were also upregulated
during the final stage of HeV infection in the brain, and only
IFN-, IL-10, and IL-1 expression was downregulated during
the first 3 to 5 days p.i. (Fig. 9D to F). TNF- expression
peaked at 1 to 2 days prior to the moribund stage of both HeV
and NiV infection (Fig. 9G). Interestingly, while chemokine
and cytokine expression generally peaked during the final stage
of high-dose NiV and HeV infection in the lung as well as
low-dose HeV infection in the brain, peak expression in the
brains of animals infected with a low dose of NiV was observed
generally 2 days prior to the moribund stage of disease.
DISCUSSION
Hendra and Nipah viruses are newly emerging zoonotic vi-
ruses that can cause severe respiratory illness and encephalitis
in humans (18). Despite intensive studies, little is known about
the mechanisms governing the development of respiratory
and/or neurological disease. The goal of the present study was
to characterize the respiratory and neurological disease man-
ifestations in the hamster model and to study the role of the
host response in HeV and NiV pathogenesis.
While several animals models have been described for both
FIG. 6. Brain lesions in animals infected with a low dose of Nipah virus (NiV) and Hendra virus (HeV) compared with those in PBS control
animals. NiV- and HeV-infected hamsters were euthanized on days 10 and 7 p.i., respectively, and lung sections were stained with H&E and stained
for NiV and HeV nucleoprotein (NP; insets) as described in Materials and Methods. Light photographs of the meninges, hippocampus, and
cerebellum of 6-week-old hamsters inoculated with PBS, NiV, or HeV are shown. Meninges: magnification, 20. Hippocampus: magnification,
10. Arrow for NiV, areas of hemorrhage and malacia; arrow for HeV, single cell neuronal necrosis. Cerebellum: NiV, magnification, 10; HeV,
magnification, 20.
FIG. 7. Blood vessels, neurons, and glial cells are immunoreactive in animals infected with low-dose HeV and NiV. Brain sections were stained
for NiV and HeV NP as described in Materials and Methods. (A) Viral NP expression in endothelial cells of small blood vessels throughout the
cerebellum of HeV-infected hamsters on day 6 p.i. Magnification, 100. (B) Viral NP expression in neurons of HeV-infected hamsters on day
7 p.i., including both cell bodies (open arrow) and dendrites (arrowhead), as well as endothelial cells of small blood vessels (closed arrow),
magnification, 40. (C) Viral NP expression in glial cells of HeV-infected hamsters on day 6 p.i., magnification, 100.
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HeV and the related NiV, studies on pathogenesis and the
development of effective therapeutics have been somewhat
limited due to biocontainment restrictions for work with these
infectious agents (34). Recently, uniformly lethal nonhuman
primate (NHP) models were described for HeV and NiV that
recapitulated both the respiratory and neurological compo-
nents of disease (11, 29). Interestingly, ribavirin treatment of
HeV-infected NHP effectively lowered virus titers which ap-
parently precluded the development of respiratory signs (29).
The treatment did not seem to prevent systemic spread of the
virus, and infection of the central nervous system (CNS) could
be established (29). We hypothesized that the infectious dose
determines the clinical outcome of NiV and HeV infection.
Hamsters have been shown to recapitulate acute HeV and
NiV infections, as seen with humans, developing severe respi-
ratory disease and encephalitis (13, 35), and have been used in
several studies to successfully test antiviral therapeutic strate-
gies (12, 13, 26). However, the clinical aspect of these infec-
tions and the effect of the challenge route and dose have not
been well studied. In the current study a high-dose intranasal
challenge with either NiV or HeV resulted in severe acute
respiratory distress, with lesions and radiological changes ap-
pearing as early as 1 day p.i. While HeV and NiV replicated
primarily in the respiratory tract, low-level systemic infection
was detected, based on the presence of virus in the periphery
following i.n. challenge, in agreement with observations in
NHP and human cases (11, 29, 36, 37). NiV infection of the
respiratory tract was initiated in the trachea as early as day 1,
progressed down the respiratory tract, infecting the bronchial
epithelium, and finally caused severe hemorrhagic pneumonia,
including the characteristic syncytium formation in the pulmo-
nary endothelium. In contrast, HeV infection was initiated
primarily in the interstitium of the lungs and not in the trachea
or bronchi. Endothelial cells have previously been identified as
an important target of infection; however, this was based on
observations from lethal human cases of HeV and NiV and
therefore represents only the final stages of the disease (20, 36,
37). Our data clearly show that while endothelial cells are an
important target of HeV and NiV infection during the late
stages of disease, the respiratory epithelium is the primary
target of HeV and NiV infection. The observation that NiV but
not HeV can replicate efficiently in the upper respiratory tract
may also have implications for the transmissibility of these
viruses, with NiV being potentially more transmissible com-
pared to HeV. These differences in initial sites of replication
may explain the fact that human-to-human transmission has
been observed only during outbreaks of NiV but not HeV
infection (2, 10, 14). Initiation of HeV infection would require
the virus to reach the lower respiratory tract, making transmis-
sion less efficient. This is similar to the observations that effi-
ciently transmitted seasonal and pandemic influenza viruses
attach better to the upper respiratory tract epithelium, whereas
avian influenza viruses do not (32), as well as to the observa-
tion of the adaptation of severe acute respiratory syndrome
coronavirus (SARS-CoV) to efficiently replicate in the human
upper respiratory tract epithelium (31). Studies of the trans-
missibility of these viruses are currently ongoing.
A low-dose i.n. challenge of HeV in hamsters resulted in a
slower onset of clinical signs, allowing for systemic spread of
the virus and ultimately the development of both respiratory
and neurological disease. Interestingly, NiV infection resulted
in a transient respiratory infection followed by the develop-
ment of neurological signs. This is similar to observations with
humans in which HeV and NiV cases initially present with ILI,
which can progress to encephalitic manifestations (18, 36). The
observed systemic spread of NiV and HeV to other organs
suggests a viremic stage during infection. While we were un-
able to recover infectious virus from the blood of infected
animals, HeV RNA has been detected in this model previ-
ously, suggesting the low-level presence of virus (13). HeV and
NiV infection of the CNS and the development of neurological
signs were associated with the disruption of the BBB. It has
been shown previously that Nipah virus can invade the CNS of
pigs by crossing the blood-brain barrier after initial virus rep-
lication in the upper respiratory tract (33); to our knowledge,
this is the first description of BBB disruption by HeV and NiV,
and studies are ongoing to determine whether this disruption is
the direct or indirect effect of virus infection.
Several cytokines and especially IP-10 were upregulated dur-
FIG. 8. Blood-brain barrier permeability is associated with neuro-
logical disease following NiV and HeV infection. Hamsters inoculated
with PBS, NiV, or HeV were injected with Evans blue 24 h prior to
euthanasia as described in Materials and Methods. Evans blue was
detected on the dorsal and ventral sides of the brains of NiV- and
HeV-infected animals due to an increase in blood-brain barrier
permeability.
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FIG. 9. Host gene expression in the lungs and brains of hamsters following NiV and HeV infection. Quantitative RT-PCR for IL-1 (A), IP-10
(B), IL-4 (C), IFN- (D), IL-6 (E), TNF- (F), and IL-10 (G) was performed on lung samples (● and ) from groups of 5 hamsters infected with
a high dose of NiV (black) or HeV (gray) and brain samples ( and ) from hamsters infected with a low dose of NiV (black) or HeV (gray). The
data are shown as changes over mock-infected controls. The error bars represent standard deviations. *, significantly different from PBS controls,
P 	 0.05; analysis of variance (ANOVA).
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ing henipavirus infection in both respiratory and CNS tissues.
Expression of IP-10 was highly upregulated in both lung and
brain tissue and was associated with virus replication in these
tissues. The upregulation of IP-10 also correlated with the
influx of inflammatory cells observed with both these tissues.
Upregulation of IP-10, IL-1, IL-6, TNF-, and IFN- in the
lungs has been described to play a role in the pathogenesis of
several respiratory virus infections, including SARS-CoV and
H5N1 (3, 6, 28). These inflammatory mediators also play an
important role in acute respiratory distress syndrome (ARDS)
pathophysiology (27). In the brain, the timing of TNF- and
IL-1 upregulation followed the first occurrence of infectious
NiV and HeV in the brain. The proinflammatory cytokines
TNF- and IL-1 have been shown to play an important role
in the induction of neuronal injury and death as well as in-
crease the permeability of the blood-brain barrier (5). Both
cytokines can be released by microglia, which were also shown
to be infected by NiV and HeV in this study (5).
In addition to the potential role of TNF- in the pathogen-
esis of NiV- and HeV-induced neurological disease, it may also
serve as a biomarker for the lethal outcome of NiV and HeV
infection, as it was typically upregulated in both lungs and the
brain 1 to 2 days prior to death. To our knowledge this is the
first characterization of the host responses against HeV and
NiV infection.
Previous studies, describing the hamster model of HeV and
NiV, focused on a general description of the pathogenesis and
the similarities between the two viruses for the establishment
of robust challenge models to evaluate vaccine and therapeutic
approaches (13, 35). Interestingly, the LD50 determined for the
i.n. challenge route in this study is 
2,000-fold lower than that
from a previous study (35). While this difference could be due
to possible genetic differences between the NiV challenge
stocks, a more likely explanation is the difference in challenge
volumes for the i.n. route. The 3-fold-higher volume used in
the current study ensures inoculation of the viruses deep into
the lungs and establishes a more robust and uniform infection,
similar to what was seen with infection with SARS-CoV and
influenza virus in mice (unpublished data; 17).
This study clearly shows that differences in the clinical out-
come of disease can be achieved by only changing the initial
challenge dose. Previous epidemiological studies have shown
significant differences in clinical presentations between the ini-
tial outbreaks of NiV in Malaysia and the subsequent out-
breaks in Bangladesh (18). The Bangladesh strain of NiV was
associated with a higher prevalence of respiratory distress
(70%) than that of the Malaysia strain (14 to 27%). While
these observed differences could be due to genetic differences
between the two NiV strains, our data suggest that the trans-
mission route and dose can also affect the clinical outcome.
Direct contact with infected pigs was a major risk factor in the
Malaysia outbreaks (24), whereas human-to-human and bat-
to-human transmission through contaminated food were major
risk factors during the Bangladesh outbreaks (14, 22). These
differences in transmission can easily affect the infectious dose
and result in different clinical presentations. Studies of the
clinical outcome of oral infection are under way.
In conclusion, our data show that differences in the infec-
tious dose result in different clinical presentations. We believe
that these models allow for more detailed studies of the patho-
genesis of respiratory or neurological disease caused by HeV
and NiV infection. In addition this study demonstrates that the
respiratory epithelium serves as the initial site of HeV and NiV
replication, which is followed by systemic spread and ultimately
infection of the CNS, and that infection of the CNS results in
the disruption of the BBB. These data provide several target
cytokines that are associated with lethal NiV and HeV infec-
tion and specifically identify IP-10, IL-1, and TNF- as im-
portant and potential targets for treatment.
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